| Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. | |
| | |
MedLine Citation:
|
PMID: 20716221 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Psoriatic plaques present a complex expression profile, including high levels of cytokines, chemokines and growth factors. Circulating cytokines have been suggested to reflect the activation status of the inflammatory process. OBJECTIVES: To analyse 20 cytokines, chemokines and growth factors in 14 patients with psoriasis vulgaris at the start and during the course of ultraviolet B treatment. METHODS: A multiplex cytokine assay was used. RESULTS: We identified increased serum levels of epidermal growth factor (EGF) (mean 323 vs. 36·6 pg mL⁻¹, P = 0·0001), interleukin (IL)-1 receptor antagonist (mean 39·1 vs. 14·6 pg mL⁻¹, P = 0·02) and tumour necrosis factor-α (mean 7·5 vs. 4·5 pg mL⁻¹, P = 0·04) at baseline in patients with psoriasis compared with matched controls. None of these cytokines was correlated to the severity of the disease (Psoriasis Area and Severity Index) or decreased with phototherapy, suggesting that sources other than lesional skin contribute to the production of these cytokines. Using cluster analysis, we observed coordinate upregulation of EGF, IL-6, macrophage inflammatory protein-1ß and vascular endothelial growth factor. CONCLUSIONS: The sustained high expression of inflammatory circulating cytokines is a potential mechanism linking psoriasis with its extracutaneous comorbidities. |
| | |
Authors:
|
K S Anderson; S Petersson; J Wong; E Shubbar; N N Lokko; M Carlström; C Enerbäck |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The British journal of dermatology Volume: 163 ISSN: 1365-2133 ISO Abbreviation: Br. J. Dermatol. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-03 Completed Date: 2011-01-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0004041 Medline TA: Br J Dermatol Country: England |
Other Details:
|
Languages: eng Pagination: 1085-9 Citation Subset: IM |
Affiliation:
|
Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood Cytokines / blood Epidermal Growth Factor / blood* Female Humans Interleukin 1 Receptor Antagonist Protein / blood* Male Psoriasis / metabolism*, radiotherapy Severity of Illness Index Tumor Necrosis Factor-alpha / blood Ultraviolet Therapy |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cytokines; 0/Interleukin 1 Receptor Antagonist Protein; 0/Tumor Necrosis Factor-alpha; 62229-50-9/Epidermal Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tobacco smoking and hand eczema: a population-based study.
Next Document: Activating BRAF mutations in eruptive melanocytic naevi.